About

About AgonOx, Inc. Unlocking the Curative Potential of Tumor-Reactive T Cells. AgonOx, Inc. started in 2012 with the primary aim of advancing immunotherapies for cancer. The research strategy at AgonOx focuses on the interaction between T cells and tumor cells. Using bioinformatics, in-vitro, and in-vivo testing to identify and validate new therapeutic approaches. AgonOx conducts its research in laboratories at the Portland Providence Cancer Center where staff scientists work closely with oncologists, surgeons, immunologists, and vivarium staff. Ultimately this collaboration has led to two first-in-human clinical trials with the latest commencing in August 2023. The company’s lead product AGX148 is an adoptive T-cell therapy for treating patients with solid malignancies. About AgonOx, Inc. Unlocking the Curative Potential of Tumor-Reactive T Cells. AgonOx, Inc. started in 2012 with the primary aim of advancing immunotherapies for cancer. The research strategy at AgonOx focuses on the interaction between T cells and tumor cells. Using bioinformatics, in-vitro, and in-vivo testing to identify and validate new therapeutic approaches. AgonOx conducts its research in laboratories at the Portland Providence Cancer Center where staff scientists work closely with oncologists, surgeons, immunologists, and vivarium staff. Ultimately this collaboration has led to two first-in-human clinical trials with the latest commencing in August 2023. The company’s lead product AGX148 is an adoptive T-cell therapy for treating patients with solid malignancies. AgonOx, a privately held clinical-stage biotechnology company, is developing novel cancer immunotherapy cell therapeutics. ►The lead T cell therapy program, AGX148, uses patented technology to selectively sort the tumor-reactive T cells from most solid malignancies such as melanoma, H&N cancer, and breast cancer. ►This process can expand cells from as few as 1,000 T cells to as many as 40 billion, which are then used as an autologous cell therapy for patients. ►The manufacturing technique has been quite reproducible for the first 8 patients treated (averaging 25 billion cells/patient infusion) and has shown encouraging clinical results and safety data when treating patients with several types of checkpoint-refractory solid cancers. ►So far, treatment for patients with Melanoma, Thyroid, Ovarian, and Head and Neck cancers has shown promising safety and effectiveness, with tumor shrinkage observed in all 7 patients treated, including partial and complete responses.